SciVision Biotech (科妍) announced on the 26th that its proprietary Hyaluronic Acid (HA) intra-articular injections, Hyaflex Forte (single-shot) and Hyaflex (three-shot), have received medical device marketing authorization from the Kuwaiti regulatory authorities.

• Clinical Application: These products utilize SciVision’s patented CHAP (Crosslinked Hyaluronic Acid Platform) technology to lubricate joints and reduce friction in patients with degenerative osteoarthritis, effectively relieving pain and improving mobility.
• Global Footprint: While maintaining a leading position in the Taiwan market, SciVision is aggressively diversifying into Aesthetics, Geriatric Care, Surgery, and Urology across global markets to enhance its commercial valuation.

Resource: 科妍透明質酸關節注射劑取得科威特銷售許可 助緩解膝關節疼痛